AGAP2 and prostate carcinoma: The results demonstrated that the expression of lncRNA AGAP2-AS1 was significantly higher in five prostate cancer cell lines than in WPMY-1, with the highest expression detected in VCaP cells (p < 0.05) (Figure 2A) which were therefore selected as the subject of following experiments.